Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17907900 | 0.90 | TP53 (0.33) | SMN1; SMN2TP53MEN1MAPTKMT2A | |
| SCHEMBL17907901 | 0.89 | MEN1 (0.39) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17907903 | 0.78 | TRPV1 (0.33) | — | |
| SCHEMBL26265751 | 0.75 | MAPT (0.36) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL978460 | 0.69 | MEN1 (0.45) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26423009 | 0.66 | BRD4 (0.41) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL979841 | 0.65 | AR (0.54) | — | |
| SCHEMBL30189253 | 0.65 | KDM4E (0.47) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL831575 | 0.65 | KDM4E (0.47) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL19663767 | 0.65 | ALDH1A1 (0.35) | SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756109-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-13 | — | — | EP | claimed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| WO-2021097046-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| EP-1756109-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | NPC1 518/4885RAB9A 3588/4885SMN1; SMN2 4588/4885 |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | NPC1 518/4885RAB9A 3588/4885SMN1; SMN2 4588/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | NPC1 518/4885RAB9A 3588/4885SMN1; SMN2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.